United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$351.33 USD
+8.74 (2.55%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $351.47 +0.14 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth B Momentum C VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 31% (79 out of 251)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.85 | 1.58 | 9.99 |
Current Quarter Estimate | 6.33 | -1.17 | 61.00 |
Year Ago Quarter Estimate | 5.38 | -0.06 | 54.84 |
Next Quarter Estimate | 6.51 | -1.92 | 63.00 |
Next Year Estimate | 27.92 | 12.59 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 25.49 | 20.70 | 15.67 |
Next Year | 12.31 | 16.10 | 11.34 |
Last 5 Years | 21.80 | 7.80 | 8.10 |
Next 5 Years | 11.10 | 20.70 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 15.74 | -1.44 |
Price/Book (MRQ) | 2.68 | 1.59 |
Price/Cash Flow (MRFY) | 15.51 | 9.47 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | 40.87% | -61.35% |
Return on Equity (TTM) | 18.82% | -58.93% |
Debt to Equity (MRQ) | 0.02 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.